Trial Profile
A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 04 May 2016 Status changed from suspended to discontinued.
- 18 Feb 2016 New trial record